The effect of Rituximab on patients with follicular and mantle-cell lymphoma

Annals of Oncology

Volumn 11, Issue SUPPL. 1, 2000, Pages

  Ghielmini, M ^a   Hsu Schmitz, S F ^b   Burki K ^b   Pichert, G ^b   Betticher, D C ^b   Stupp, R ^b   Wernli, M ^b   Lohri, A ^b   Schmitter, D ^b   Bertoni, F ^b   Cerny, T ^b  

^a Ospedale Civico Lugano   (Switzerland)

^b NONE

Author keywords

Anti CD 20 antibody; Follicular lymphoma; Immunotherapy; Mantle cell lymphoma; Rituximab

Indexed keywords

ONCOPROTEIN; RITUXIMAB;

ADULT; AGED; BLOOD TOXICITY; BRONCHIOLITIS; CANCER IMMUNOTHERAPY; CARDIOVASCULAR DISEASE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG INDICATION; DRUG RESPONSE; FOLLICULAR LYMPHOMA; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCALCEMIA; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; TREATMENT OUTCOME;

EID: 0033996883     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/11.suppl_1.S123     Document Type: Conference Paper

References (10)

1. Piro LD, White CA, Grillo-Lopez AJ et al. Extended Rituximab (anti-CD20 monoclonal antibody) therapy for relapsed or refractory low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1999; 10: 655-61.
2. Maloney DG, Grillo-Lopez AJ, White CA et al. IDEC-C2B8 (Rituximab) anti-CD20 monoclonal antibody therapy in patients with relapsed low-grade non-Hodgkin's lymphoma. Blood 1997; 90: 2188-95.
3. Berinstein NL, Grillo-Lopez AJ, White CA et al. Association of serum Rituximab (IDEC-C2B8) concentration and anti-tumor response in the treatment of recurrent low-grade or follicular non-Hodgkin's lymphoma. Ann Oncol 1998; 9: 995-1001.
4. Tobinai K, Kobayashi Y, Narabayashi M et al. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, Rituximab) in relapsed B-cell lymphoma. Ann Oncol 1998; 9: 527-34.
5. McLaughlin P, Grillo-Lopez AJ, Link BK et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: Half of patients respond to a four-dose treatment program. J Clin Oncol 1998; 16: 2825-33.
6. Coiffier B, Haioun C, Ketterer N et al. Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: A multicenter phase II study. Blood 1998; 92: 1927-32.
7. Foran JM, Cunningham D, Coiffier B et al. Immunotherapy of mantle-cell lymphoma with Rituximab: Duration of response and analysis of factors associated with response. Ann Oncol 1999; 10: 33.
8. Widmer L, Pichert G, Jost LM, Stahel RA. Fate of contaminating t(14;18) translocation carrying lymphoma cells during ex vivo expansion of CD34-selected hematopoietic progenitor cells. Blood 1996; 88: 3166-75.
9. Bertoni F, Roggero E, Luscieti P et al. Clonality assessment in blood of patients with mantle-cell lymphoma. Leuk Lymph 1999; 32: 375-9.
10. Lopez-Guillermo A, Cabanillas F, McLaughlin P et al. The clinical significance of molecular response in indolent follicular lymphoma. Blood 1998; 91: 2955-60.